Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
For nearly 30 years, Perceptive has been at the forefront of neuroscience imaging solutions, developing and delivering cutting-edge services for over 650 preclinical, early-phase, and late-phase clinical studies across neuro-degenerative, neuro-oncology, neuro-psychiatric, and rare disease indications.
Perceptive’s image analysis team leverages industry-leading validated and exploratory tools for neuro PET, SPECT, CT, and MRI analysis pipelines supporting study endpoints. Perceptive has analyzed thousands of clinical scans across Neuroscience indications including Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Multiple Sclerosis, Neuro-oncology, and more.
Comprehensive analysis pipelines utilize SUVR, Centiloids, state-of-the-art AmyloidIQ and TauIQ as well as volumetrics, advanced Diffusion Tensor Imaging (DTI), functional Magnetic Resonance Imaging (fMRI), and neuromelanin algorithms. In addition, Perceptive supports semi-qualitative visual neuro-radiology reads.
Perceptive supports your Neuroscience studies with rigorous scientific expertise and operational excellence within the clinical trial framework.
You can rely on Perceptive to help you minimize risks and optimize Neuroscience development outcomes by:
Stay on top of industry trends and learn how Perceptive is helping sponsors and CROs design and implement clinical trials effectively – and efficiently.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
